I-16

I-16: sourced facts only. name: "we designed and developed a novel dual PARP1/ERK inhibitor, I-16, which exhibits potent and selective inhibition against both PARP1 (IC50 = 0.9 nM) and ERK2 (IC50 = 1.8 nM)." [PMID:41739621]; target: "we designed and developed a novel dual PARP1/ERK inhibitor, I-16, which exhibits potent and selective inhibition against both PARP1 (IC50 = 0.9 nM) and ERK2 (IC50 = 1.8 nM)." [PMID:41739621]; target: "we designed and developed a novel dual PARP1/ERK inhibitor, I-16, which exhibits potent and selective inhibition against both PARP1 (IC50 = 0.9 nM) and ERK2 (IC50 = 1.8 nM)." [PMID:41739621]; developer: "Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 211198, RP China." [PMID:41739621]; stage: "In an HCT116 xenograft model, I-16 (20 mg/kg) elicited significant tumor growth suppression, outperforming Olaparib (50 mg/kg) or BVD-523 (5 mg/kg) monotherapy and achieving efficacy comparable to their combination." [PMID:41739621]